The INCOGNITO Pilot Trial is a single centre pilot prospective randomized open-label blinded endpoint (PROBE) trial to assess the feasibility of a full-scale randomized trial to determine whether an occult cancer screening strategy of FDG PET/CT (F-fluorodeoxyglucose positron emission/computed tomography) in addition to usual care increases the number of occult cancers diagnosed after screening compared to usual care cancer screening alone in patients with cryptogenic stroke.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Enrollment
45
F-fluorodeoxyglucose positron emission/computed tomography
Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care
The Ottawa Hospital
Ottawa, Ontario, Canada
RECRUITINGParticipant Recruitment
Number of participants recruited
Time frame: Over 12 months
Eligibility Rate
percentage of screened patients who are eligible
Time frame: Over 12 months
Consent Rate
percentage of eligible patients who provide consent
Time frame: Over 12 months
Retention Rate
percentage of participants retained at follow-up
Time frame: Over 24 months
Study Completion Rate
percentage of participants who completed all study procedures
Time frame: Over 24 months
Adherence Rate
adherence to screening strategy
Time frame: Over 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.